Related Experiment Video

Updated: Jun 4, 2026

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders
12:49

Mutagenesis and Analysis of Genetic Mutations in the GC-rich KISS1 Receptor Sequence Identified in Humans with Reproductive Disorders

Published on: September 4, 2011

Kit gene in endometrial carcinoma: an immunohistochemical and mutational analysis

Ingrid Vandenput1, Maria Debiec-Rychter, An Capoen

  • 1Leuven Cancer Institute, Katholieke Universiteit Leuven, Belgium.

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|January 29, 2011
PubMed
Abstract

Insights

This study investigated KIT expression in endometrial carcinoma, finding no KIT expression or mutations. Therefore, imatinib mesylate is unlikely to be an effective treatment for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Recurrent endometrial carcinoma presents a significant clinical challenge.
  • Targeted treatment strategies are crucial for improving patient outcomes.
  • The receptor tyrosine kinase KIT is a potential therapeutic target.

Purpose of the Study:

  • To evaluate KIT expression and mutations in endometrial carcinoma.
  • To determine the potential efficacy of imatinib mesylate in treating endometrial carcinoma.

Main Methods:

  • Immunohistochemical analysis of KIT expression in 45 endometrial carcinoma tissue samples (30 primary, 15 recurrent).
  • Mutation analysis of KIT gene hotspot exons in 15 primary tumor samples.

Main Results:

  • No KIT expression was detected in any of the analyzed endometrial carcinoma tissues.
  • No mutations were found in the hotspot exons of the KIT gene.
  • Histopathological analysis confirmed the presence of both Type I and Type II endometrial carcinoma subtypes.

Conclusions:

  • The absence of KIT expression and mutations suggests that endometrial carcinoma is unlikely to respond to imatinib mesylate therapy.
  • KIT-targeted therapy with imatinib mesylate is not a viable treatment option for endometrial carcinoma based on these findings.
  • Further research into alternative targeted therapies for endometrial carcinoma is warranted.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.